a person who, although present at some event, does not take part in it". [2] In other words a bystander is an observer or spectator. How can a bystander provide necessary information of the patient? I think the authors need to have a relook on this statement.
In the Results section under heading "Risk factors", a comparison of frequencies of stroke risk factors among cases and controls has been provided and various risk factors have been enlisted (Table 2 of the study). [1] However, I am not sure as to how patients with comorbid conditions like diabetes and hypertension together, were placed in this list. Was it that all patients included in this study suffered from a single condition only? Did physical inactivity, smoking, and alcohol exist in isolation? A look at the numbers suggests otherwise. So how did the authors choose individual risk factors? The pattern has been repeated in Tables 3 and 4 of the study [1] .
"Comments on intravenous thrombolysis in acute ischemic stroke in a known case of left atrial myxoma" Sir, We read the paper on "Intravenous thrombolysis in a patient with left atrial myxoma with acute ischemic stroke" by Kulkarni GB, Yadav R, Mustare V and Modi S, published in Annals of Indian Academy of Neurology (Ann Indian Acad Neurol 2014;17:455-8) [1] with great interest.
We congratulate the authors for their efforts in managing this patient. It is commendable on their part to abide by the guidelines in managing a patient who presented with acute ischemic stroke (AIS) in the window period with intravenous thrombolysis.
The fact that she was a known case of left atrial myxoma (LAM), should have been considered prior to thrombolysing her, as fibrinolytic agents cannot lyse myxomatous embolic material. There is no drug treatment for atrial myxoma. The only definite treatment is surgical resection of the tumor. [2] Cardiac myxomas are associated with intracranial myxomatous aneurysms in which case the aneurysm may rupture [3] because of these reasons antithrombotic and anticoagulants are not indicated in AIS associated with atrial myxoma.
These fusiform aneurysms cannot be clipped because they lack a stem, and the only reported treatment is successful surgical excision. [4] MRI susceptibility-weighted images are three to six times more sensitive than conventional T2-weighted gradient echo images for hemosiderin detection. [5] This technology can be helpful in detecting "unruptured" aneurysms, when there is a suspicion. Patients with cardiac myxoma should be observed for myxoma-related cerebral aneurysms, which can develop and grow [6] even after the tumor is resected. Hence, long-term regular follow-up of these patients is recommended.
We wish to reemphasize the fact that thrombolysis with recombinant tissue plasminogen activator (rTPA) is not indicated for myxoma-related AIS and is in fact harmful, and should not be offered to known patients of myxoma presenting with AIS. Sir, Thank you very much for your comments and subsequent discussion regarding the article. [1] Our patient had declined to the surgical removal of the myxoma when it was detected during routine screening prior to her stroke. Even during her last follow-up visit she was not willing for the surgery. As we have highlighted there are very few reported cases of left atrial myxoma (LAM) with acute ischemic stroke (AIS) undergoing thrombolysis. Out of the reported 10 patients (apart from our patient) six have undergone intravenous thrombolysis (IVT) and in four of them there was an improvement, one did not improve and one patient bled. Because of small number of patients it is difficult to generalize the utility of IVT, even though it appears to be helpful. The mechanism of stroke in these patients may be due to embolism of the clot or tumor tissue or aneurysmal rupture. [2, 3] In our patient, computed tomography (CT) at presentation did not reveal hemorrhage, with subsequent magnetic resonance angiography (MRA) ruling out aneurysm. In our patient Echo showed myxoma with thrombus and she improved initially with IVT, suggesting probably it was blood clot rather than tumorous tissue causing the symptoms. During the window period it will be difficult to ascertain whether the tumor/clot embolism is responsible for the symptoms. Interventional management with chemical and/or mechanical thrombolysis may be thought of; but availability of the facility, expertise, and cost will be a challenge in majority of the hospitals in our country. We conclude by responding that it is a rare situation we may encounter, approach should be individualized to each patient taking into account of hospital setting and patients expectations. Combined care from neurologist and cardiologist will definitely help in better outcome in this condition.
